Quetiapine for the treatment of bipolar II depression: Analysis of data from two randomized, double-blind, placebo-controlled studies

References

• American Psychiatric Association. 1994. Diagnostic and statistical manual of mental disorders. 4th edition (DSM-IV). Washington, DC: American Psychiatric Press.
   Google Scholar
• American Psychiatric Association. 2002. Practice guidelines for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 159:1–50.
   Web of Science ®Google Scholar
• Amsterdam JD, Brunswick DJ. Antidepressant monotherapy for bipolar type II major depression. Bipolar Disord 2003; 5: 388–395
   PubMedGoogle Scholar
• Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord 1998; 50: 143–151
   PubMed Web of Science ®Google Scholar
• Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672–676
   PubMed Web of Science ®Google Scholar
• Berk M, Dodd S. Bipolar II disorder: a review. Bipolar Disord 2004; 7: 11–21
   Google Scholar
• Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SF, Kupfer DJ 1989. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28:193–213.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Keck PE, Jr, Macfadden W; for the BOLDER Study Group, et al. 2005. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 162:1351–1360.
   PubMed Web of Science ®Google Scholar
• Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993; 29: 321–326
   PubMed Web of Science ®Google Scholar
• Goodwin GM; Consensus Group of the British Association for Psychopharmacology. 2003. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 17:149–173.
   PubMedGoogle Scholar
• Grunze H, Kasper S, Goodwin G, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: treatment of bipolar depression. World J Biol Psychiatry 2002; 3: 115–124
   PubMedGoogle Scholar
• Guy W, editor. 1976. ECDEU Assessment manual of psychopharmacology: Publication ADM 76–338. Washington, DC: US Department of Health, Education, and Welfare. p 218–222.
   Google Scholar
• Hadjipavlou G, Mok H, Yatham LN. Pharmacotherapy of bipolar II disorder: a critical review of current evidence. Bipolar Disord 2004; 6: 14–25
   PubMed Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62
   PubMed Web of Science ®Google Scholar
• Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003; 60: 261–269
   PubMed Web of Science ®Google Scholar
• Keck, Jr PE, Perlis RH, Otto ME, Carpenter D, Ross R, Docherty JP 2004. The Expert Consensus Guidelines Series: Treatment of Bipolar Disorder 2004. Postgrad Med Special Rep 1–120.
   Google Scholar
• Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593–602
   PubMed Web of Science ®Google Scholar
• Kupka RW, Luckenbaugh DA, Post RM, et al. Comparison of rapid-cycling and non-rapid-cycling bipolar disorder based on prospective mood ratings in 539 outpatients. Am J Psychiatry 2005; 162: 1273–1280
   PubMed Web of Science ®Google Scholar
• Mallinckrodt CH, Clark WS, Carroll RJ, Molenberghs. 2003. Assessing response profiles from incomplete longitudinal clinical trial data under regulatory consideration. J Biopharm Stat 13:179–190.
   PubMedGoogle Scholar
• Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–389
   PubMed Web of Science ®Google Scholar
• Sheehan DV. The anxiety disease. Scribner's, New York 1983
   Google Scholar
• Simpson GN, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970; 212(Suppl 44)11–19
   Google Scholar
• Suppes T, Dennehy EB. Evidence-based long-term treatment of bipolar II disorder. J Clin Psychiatry 2002; 63(Suppl 10)29–33
   PubMedGoogle Scholar
• Suppes T, Ozcan ME, Carmody T. Response to clozapine of rapid cycling versus non-cycling patients with a history of mania. Bipolar Disord 2004; 6: 329–332
   PubMedGoogle Scholar
• Suppes T, Dennehy EB, Hirschfeld RM, et al. The Texas Implementation of Medication Algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 2005a; 66: 870–886
   PubMed Web of Science ®Google Scholar
• Suppes T, Brown E, Schuh LM, Baker RW, Tohen M. Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: post hoc analyses of 47-week data. J Affect Disord 2005b; 89: 69–77
   PubMed Web of Science ®Google Scholar
• Thase ME, Macfadden W, Weisler RH; for the BOLDER II Study Group, et al. 2006. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 26:600–609.
   PubMed Web of Science ®Google Scholar
• Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60: 1079–1088
   PubMed Web of Science ®Google Scholar
• Valtonen H, Suominen K, Mantere O, Leppamaki S, Arvilommi O, Isometsa ET. Suicidal ideation and attempts in bipolar I and II disorders. J Clin Psychiatry 2005; 66: 1456–1462
   PubMed Web of Science ®Google Scholar
• Vieta E, Carné X. The use of placebo in clinical trials on bipolar disorder: a new approach for an old debate. Psychother Psychosom 2005; 74: 10–16
   PubMed Web of Science ®Google Scholar
• Vieta E, Calabrese JR, Hennen J, et al. Comparison of rapid-cycling and non–rapid cycling bipolar I mania patients during treatment with olanzapine: analysis of pooled data. J Clin Psychiatry 2004; 65: 1420–1428
   PubMed Web of Science ®Google Scholar
• Vieta E, Gasto C, Colom F, et al. Role of risperidone in bipolar II: an open 6–month study. J Affect Disord 2001; 67: 213–219
   PubMed Web of Science ®Google Scholar
• Weisler R, Arvekvist R, Stening G, Macfadden W 2006. Quetiapine monotherapy is efficacious for depressive episodes of bipolar I disorder: combined results from two double-blind, placebo-controlled studies. Poster presented at the American Psychiatric Association's 159th Annual Meeting, Toronto, Ontario, Canada, 20–25 May.
   Google Scholar
• Yatham LN. Diagnosis and management of patients with bipolar II disorder. J Clin Psychiatry 2005; 66(Suppl 1)13–17
   PubMedGoogle Scholar
• Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 2005; 7(Suppl 3)5–69
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord 2006; 8: 721–739
   PubMed Web of Science ®Google Scholar
• Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429–435
   PubMed Web of Science ®Google Scholar